Monte Rosa Q1 net income $46.9M on Novartis revenue; pipeline advances

Monte Rosa Therapeutics, Inc.

Net income of $46.9M vs net loss of $32.0M a year ago; collaboration revenue $84.9M from Novartis.
Cash, equivalents, and securities $331M; expected to fund operations into 2028.
MRT-6160 (VAV1) advancing to Phase 2 with Novartis; up to $2.1B in milestones.
MRT-2359 (GSPT1) shows clinical signals in CRPC; additional data expected H2 2025.
IND filing for MRT-8102 (NEK7) on track H1 2025; CDK2/CCNE1 IND planned for 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.